We are live on ! Find out more
MCRB icon

Seres Therapeutics
MCRB

63 hedge funds and large institutions have $43.1M invested in Seres Therapeutics in 2025 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 16 increasing their positions, 14 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

238% more call options, than puts

Call options by funds: $132K | Put options by funds: $39K

14% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 14

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.08% less ownership

Funds ownership: 1.85% → 1.76% (-0.08%)

9% less funds holding

Funds holding: 69 → 63 (-6)

18% less capital invested

Capital invested by funds: $52.5M → $43.1M (-$9.41M)

55% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 11

Holders
63
Holders Change
-6
Holders Change %
-8.7%
% of All Funds
0.84%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
5
Increased
16
Reduced
14
Closed
11
Calls
$132K
Puts
$39K
Net Calls
+$93K
Net Calls Change
-$2.38M

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$872K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$305K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$171K
4
TCM
Tang Capital Management
California
+$160K
5
Vontobel Holding
Vontobel Holding
Switzerland
+$116K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$1.46M
2
Millennium Management
Millennium Management
New York
-$1.39M
3
HighTower Advisors
HighTower Advisors
Illinois
-$58.2K
4
Jane Street
Jane Street
New York
-$48.8K
5
CF
Cantor Fitzgerald
New York
-$45.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
51
JP Morgan Chase
New York
$913 – – –
TFM
52
TFC Financial Management
Massachusetts
$701 – – –
CA
53
Continuum Advisory
Idaho
$669 – – –
EWA
54
EverSource Wealth Advisors
Alabama
$466 – – –
SSB
55
Sandy Spring Bank
Maryland
$242 – – –
Citigroup
56
Citigroup
New York
$151 -$2.71K -173 -94%
Nisa Investment Advisors
57
Nisa Investment Advisors
Missouri
$140 -$78 -5 -33%
FFA
58
Farther Finance Advisors
California
$138 – – –
SIS
59
Sound Income Strategies
Florida
$123 – – –
Osaic Holdings
60
Osaic Holdings
Arizona
$112 -$188 -12 -60%
Jones Financial Companies
61
Jones Financial Companies
Missouri
$35 – – –
Citadel Advisors
62
Citadel Advisors
Florida
$34 – – –
WT
63
Whittier Trust
California
$21 – – –
HighTower Advisors
64
HighTower Advisors
Illinois
– -$58.2K -3,500 Closed
Jane Street
65
Jane Street
New York
– -$48.8K -2,937 Closed
HF
66
HRT Financial
New York
– -$22K -1,343 Closed
CFM
67
Catalyst Funds Management
Australia
– -$20.7K -1,245 Closed
Simplex Trading
68
Simplex Trading
Illinois
– -$19.4K -1,238 Closed
XT
69
XTX Topco
Cayman Islands
– -$13.5K -815 Closed
CCFM
70
Clear Creek Financial Management
Washington
– -$10.8K -648 Closed
TRCT
71
Tower Research Capital (TRC)
New York
– -$7.75K -466 Closed
PNC Financial Services Group
72
PNC Financial Services Group
Pennsylvania
– -$529 -32 Closed
BIA
73
Bell Investment Advisors
California
– -$508 -31 Closed
LFG
74
Larson Financial Group
Missouri
– -$195 -12 Closed
1 2
3

MCRB Hedge Fund Activity: Q1 2025 in Review

63 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q1 2025, worth a combined $43.1M — down 18% from $52.5M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of MCRB and 5 opened new positions — a net loss of 6 holders — while 14 trimmed existing stakes and 16 added.

The largest buyer was UBS Group, adding an estimated $872K. The largest seller was Morgan Stanley, cutting an estimated $1.46M.

  • 63 institutional investors held Seres Therapeutics (MCRB) as of Q1 2025, down from 69 in Q4 2024.
  • Funds reported $43.1M of Seres Therapeutics stock for Q1 2025, down 18% quarter-over-quarter.
  • 5 funds opened new Seres Therapeutics positions in Q1 2025 and 11 closed out, a net change of -6 holders.
  • The largest Seres Therapeutics buyer in Q1 2025 was UBS Group, an estimated $872K added.
  • The largest Seres Therapeutics seller in Q1 2025 was Morgan Stanley, an estimated $1.46M sold.

Based on aggregated 13F filings for Q1 2025.